Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021145552 - THERAPEUTIC USE OF LONG-ACTING CONJUGATE OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON AND GLP-1 AND GIP RECEPTORS AGAINST LUNG DISEASE

Publication Number WO/2021/145552
Publication Date 22.07.2021
International Application No. PCT/KR2020/016535
International Filing Date 20.11.2020
IPC
A61K 38/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K 47/68 2017.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 11/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61K 38/17 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 38/26 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
26Glucagons
A61K 38/22 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
Applicants
  • 한미약품 주식회사 HANMI PHARM. CO., LTD. [KR]/[KR]
Inventors
  • 이선명 LEE, Seon Myeong
  • 이종석 LEE, Jong Suk
  • 김정국 KIM, Jung Kuk
  • 이상현 LEE, Sang Hyun
  • 오의림 OH, Euh Lim
  • 조효상 JO, Hyo Sang
  • 박은진 PARK, Eun Jin
  • 임종윤 LIM, Chong Yoon
Agents
  • 특허법인한얼 HANOL INTELLECTUAL PROPERTY AND LAW
Priority Data
10-2020-000437913.01.2020KR
10-2020-013434416.10.2020KR
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) THERAPEUTIC USE OF LONG-ACTING CONJUGATE OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON AND GLP-1 AND GIP RECEPTORS AGAINST LUNG DISEASE
(FR) UTILISATION THÉRAPEUTIQUE POUR LES MALADIES HÉPATHIQUES, D'UN TRIPLE AGONISTE AYANT UNE ACTIVITÉ PAR RAPPORT À TOUS LES RÉCEPTEURS DU GLUCAGON, DU GLP-1 ET DU GIP CONTRE LES MALADIES PULMONAIRES
(KO) 글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 폐질환의 치료 용도
Abstract
(EN)
The present invention relates to a preventive or therapeutic use of a triple agonist and/or a conjugate thereof against lung disease, the triple agonist and/or conjugate thereof having activity with respect to all of glucagon and the GLP-1 and GIP receptors.
(FR)
La présente invention concerne une utilisation préventive ou thérapeutique d'un triple agoniste et/ou d'un conjugué de celui-ci contre une pneumopathie, l'agoniste triple et/ou le conjugué de ceux-ci ayant une activité par rapport à l'ensemble du glucagon et des récepteurs du GLP-1 et du GIP.
(KO)
본 발명은 글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체 및/또는 이의 결합체의 폐 질환에 대한 예방 또는 치료적 용도에 관한 것이다.
Latest bibliographic data on file with the International Bureau